A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC) Meeting Abstract
| Authors: | Spigel, D. R.; Reckamp, K. L.; Rizvi, N. A.; Poddubskaya, E.; West, H. J.; Eberhardt, W. E. E.; Baas, P.; Antonia, S. J.; Pluzanski, A.; Vokes, E. E.; Holgado, E.; Waterhouse, D. M.; Ready, N.; Gainor, J. F.; Aren, O. R.; Horn, L.; Paz-Ares, L.; Baudelet, C.; Lestini, B. J.; Brahmer, J. R. |
| Abstract Title: | A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC) |
| Meeting Title: | 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2015 May 29-Jun 2 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358036901722 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2015.33.15_suppl.8009 |
| Notes: | Meeting Abstract: 8009 -- Source: Wos |
